Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat.

Ayyar VS, Song D, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):318-326. doi: 10.1124/jpet.119.257519. Epub 2019 Jun 13.

PMID:
31197020
2.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression.

Ayyar VS, DuBois DC, Nakamura T, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):327-336. doi: 10.1124/jpet.119.257527. Epub 2019 Jun 13. Erratum in: J Pharmacol Exp Ther. 2019 Sep;370(3):436.

PMID:
31197019
3.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids.

Ayyar VS, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):337-349. doi: 10.1124/jpet.119.257543. Epub 2019 Jun 13.

PMID:
31197018
4.

ATLAS mPBPK: a MATLAb-based tool for modeling and Simulation of minimal Physiologically Based PharmacoKinetic models.

Mavroudis PD, Ayyar VS, Jusko WJ.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 2. doi: 10.1002/psp4.12441. [Epub ahead of print]

5.

Indirect pharmacodynamic models for responses with circadian removal.

Ayyar VS, Krzyzanski W, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2019 Feb;46(1):89-101. doi: 10.1007/s10928-019-09620-z. Epub 2019 Jan 29.

PMID:
30694437
6.

Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver.

Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2018 Oct;367(1):168-183. doi: 10.1124/jpet.118.251959. Epub 2018 Aug 7.

PMID:
30087156
7.

Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Qu J, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):557-575. doi: 10.1007/s10928-018-9585-x. Epub 2018 Apr 27.

PMID:
29704219
8.

Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics.

Ayyar VS, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2017 Oct;363(1):45-57. doi: 10.1124/jpet.117.242990. Epub 2017 Jul 20.

9.

Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism.

Ayyar VS, Almon RR, DuBois DC, Sukumaran S, Qu J, Jusko WJ.

J Proteomics. 2017 May 8;160:84-105. doi: 10.1016/j.jprot.2017.03.007. Epub 2017 Mar 14.

10.

Quantitative tissue-specific dynamics of in vivo GILZ mRNA expression and regulation by endogenous and exogenous glucocorticoids.

Ayyar VS, Almon RR, Jusko WJ, DuBois DC.

Physiol Rep. 2015 Jun;3(6). pii: e12382. doi: 10.14814/phy2.12382.

11.

Russell Silver syndrome: a perspective on growth and the influence of growth hormone therapy.

Mascarenhas JV, Ayyar VS.

Indian J Endocrinol Metab. 2012 Sep;16(5):840-2. doi: 10.4103/2230-8210.100675.

12.

Type 2 DM is not coronary artery disease equivalent.

Ayyar VS.

Indian J Endocrinol Metab. 2012 May;16(3):472. doi: 10.4103/2230-8210.95718. No abstract available.

13.

History of growth hormone therapy.

Ayyar VS.

Indian J Endocrinol Metab. 2011 Sep;15 Suppl 3:S162-5. doi: 10.4103/2230-8210.84852.

Supplemental Content

Loading ...
Support Center